जर्नल ऑफ इंटरवेंशनल एंड जनरल कार्डियोलॉजी

Rheumatoid arthritis is an autoimmune disease that primarily affects the joints. It is characterized by chronic inflammation, pain, stiffness, and joint deformity. RA is not limited to the joints, as it can also affect other organs and systems in the body, including the cardiovascular system. Over the years, extensive research has revealed a significant association between RA and an increased risk of cardiovascular disease. Individuals with RA have a higher likelihood of experiencing heart attacks, strokes, and other cardiovascular events compared to the general population. Inflammation plays a central role in the pathophysiology of RA, contributing to joint damage and systemic complications. The chronic inflammation observed in RA can lead to endothelial dysfunction, atherosclerosis and increased cardiovascular risk.

Cardiovascular disease remains a leading cause of mortality worldwide. Implantable cardioverter defibrillators have become a crucial component of managing certain high-risk CVD patients, primarily those with a history of ventricular arrhythmias or cardiac arrest. However, despite advances in technology and the life-saving potential of ICDs, not all patients derive the same benefit from these devices. Recent research has suggested that nighttime heart rate, a previously underexplored parameter, may have prognostic significance in patients with ICDs. This article delves into the association between nighttime heart rate and cardiovascular mortality in patients with ICDs, exploring the potential implications for risk stratification and patient management. ICDs are specialized devices designed to treat life-threatening ventricular arrhythmias, particularly ventricular tachycardia and ventricular fibrillation.

The global population is aging rapidly, and the number of octogenarians is steadily increasing. With aging, the risk of cardiovascular diseases also rises. As a result, many octogenarians require multiple medications to manage their cardiovascular health. This situation often leads to polypharmacy, which is the concurrent use of multiple medications by a single individual. While polypharmacy can be necessary for managing complex health conditions, it also poses challenges, including drug interactions, adverse effects and potential impacts on prognosis. In this article, we will explore the prognostic impact of cardiovascular polypharmacy on octogenarians, examining the complexities, potential benefits, and risks associated with managing multiple medications in this vulnerable population. The world's population is experiencing a demographic shift, with a growing proportion of individuals living well into their 80s and beyond.

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with aging being a significant risk factor. As the global population continues to age, understanding the mechanisms underlying age-related cardiovascular dysfunction and identifying novel therapeutic targets is of paramount importance. One promising avenue of research involves the study of a group of proteins known as sirtuins. Sirtuins are emerging as critical regulators of cellular homeostasis and longevity, and their role in age-related cardiovascular dysfunction is gaining increasing attention. This article explores the role of SIRT1 as a novel target for age-related cardiovascular dysfunction, delving into its mechanisms of action, potential therapeutic implications, and avenues for further research.